• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ATS Roundup: Emulate models viral infection in “asthma-on-a-chip”

May 24, 2017 By Sarah Faulkner

Sunovion Pharmaceuticals touts data for COPD therapies

Sunovion PharmaceuticalsSunovion Pharmaceuticals highlighted Phase III data for its investigational eFlow closed-system nebulizer in patients with moderate-to-very severe chronic obstructive pulmonary disease.

The company said a long-term safety trial of eFlow demonstrated a high rate of patient-reported satisfaction and confidence with the use of the system. If it’s approved, eFlow would be the 1st nebulized long-acting muscarinic antagonists for use as a treatment for COPD in the U.S. The system allows patients to breathe normally while using the device and is designed to administer medication in 2 to 3 minutes.

“There are no approved nebulized, long-acting muscarinic antagonists (LAMAs) currently available for use in COPD,” Thomas Goodin, senior director of clinical development, said in prepared remarks. “These data suggest that for moderate-to-very severe patients, SUN-101/eFlow could potentially be an effective and well-tolerated maintenance therapy.”

“COPD symptoms can severely impact patients’ daily activities and health related quality of life, and it is important for any treatment to be not only well-tolerated and effective, but also easy to administer,” principal investigator Dr. Gary Ferguson added. “With its efficacy and tolerability profile as well as the portability and short administration time, SUN-101/eFlow could be a valuable treatment option for patients with COPD.”

Sunovion also presented Phase III data for its Utibron Neohaler inhalation powder, which showed that the indacaterol/glycopyrrolate therapy improved lung function, health-related quality of life, dyspnea and night-time symptoms compared to placebo in patients with moderate-to-severe chronic obstructive pulmonary disease.

“Improvement in health related quality of life, including reduction of difficult or labored breathing, is a key therapeutic goal for patients with COPD that is reflected in the updated 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) report,” lead investigator Dr. Donald Mahler said in prepared remarks. “These Utibron Neohaler data show that the dual bronchodilator significantly improves and sustains bronchodilation and may improve health status and COPD symptoms in moderate-to-severe patients.”

“Utibron Neohaler has demonstrated the value of dual bronchodilation treatment for people living with COPD,” Goodin added. “The data presented at ATS indicate that Utibron Neohaler was associated with statistically significant and clinically important improvements in lung function as well as a reduction in the number of sleep disturbances and in the use of rescue medication, which may have a positive impact on patients’ quality of life.”

NEXT: Bellerophon highlights Phase II data for INOpulse system

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Emulate Inc, Merck, Mylan, pulmonx, Sunovion Pharmaceuticals, Theravance Biopharma

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS